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SHORT COMMUNICATION
Adrenal failure in patients with breast carcinoma after long-term
treatment of cyclic alternating oestrogen progesterone
V. Hug, S. Kau, G.N. Hortobagyi & L. Jones
Department ofMedical Oncology (Breast Medical Oncology), and Gynecology, The University of Texas, M.D. Anderson Cancer
Center, Houston, Texas 77030, USA.
Long-term endocrine treatments for breast carcinoma may
not be as innocuous as generally thought, because hormones
not only interact with tumour targets, but also with
physiological targets. Furthermore, as tissue concentrations
increase into the pharmacological dose range, the specificity
of many hormones gets lost (Blossey et al., 1984); and spill-
over of hormones to structurally related receptors can induce
nonphysiological endocrine events. Thus, complex synergistic
and antagonistic interactions can result from the therapeutic
use of hormones, particularly if used in combination.
Progestins are among the most effective hormonal agents
for the treatment of breast carcinoma. They act on tumour
targets by inhibiting the proliferative activity of susceptible
breast tumour cells. After it became known that oestrogen-
priming of susceptible tumour cells enhances their expression
of progesterone receptors and thereby sensitises them to the
antiproliferative effect of progestins (Vingnon et al., 1983),
the benefit of administering progestins to patients with breast
carcinoma after a brief exposure of tumours to oestrogen was
also explored (Rochefort, 1984 and Pannuti et al., 1987).
Manifestations of clinical adrenal insufficiency have rarely
been reported, in spite of the fact that their use in high-dose
or in alternating sequence has become clinical practice
(Siminoski et al., 1989; Donckier et al., 1990, Willemse et al.,
1990, and van Veelen et al., 1984, 1985a and 1985b).
In contrast, we observed three patients developing clinical
manifestations of acute adrenal insufficiency among 30
patients treated with cyclic-alternating oestradiol and
medroxyprogesterone acetate (Hortobagyi et al., 1989). This
complication developed in 18% of patients (3 of 17) who
received treatment for periods longer than 4 months. Patients
who developed symptoms of adrenal insufficiency tended to
be older, tended to receive treatment for longer, and were
significantly more sensitive to the treatment toxicities than
patients who did not. This analysis forms the basis of our
report.
Thirty patients with oestrogen receptor positive (20) or
oestrogen receptor unknown (10) stage IV breast carcinoma
were treated with cyclic-alternating hormones of oestradiol
and medroxyprogesterone acetate. All patients were post-
menopausal. The median age of patients was 64 years, and
ranged between 32 and 76 years. Their median performance
status was one by the Zubrod scale (Zubrod et al., 1960), and
ranged between 0 and 3. Treatment consisted of 50 mcg of
oestradiol p.o. daily for 7 days followed by 400 mg of
medroxyprogesterone acetate p.o. daily for 21 days. After a
1-week rest period, cycles were repeated. Treatment was
administered for the duration of tumour response. The UICC
criteria of response were used to evaluate the treatment effect
(Hayward et al., 1977).
Treatment of cyclic-alternating oestradiol and medroxy-
progesterone acetate was administered for a median duration
of 8 months (range, 1-71 + months). Seventeen patients re-
sponded to treatment, and these patients received treatment
for a median duration of 17 months (range, 4-71 + months).
Among the 17 responding patients, three developed clinical
signs and symptoms of acute adrenal insufficiency towards
the end of treatment or upon its withdrawal. Symptomatic
patients were more sensitive to the anabolic effects of pro-
gesterone than asymptomatic patients, as reflected by a
higher rise in hematocrit and weight during treatment. Table
I illustrates this association. The plasma levels of the perti-
nent pituitary and adrenal hormones, determined at diagnosis
of adrenal decompensation and at follow-up 11 to 6 months
later, are summarised in Table III. The clinical course of the
three patients was as follows:
Case 1: The first patient was a 75-year-old woman with a
21-year history ofbilateral breast carcinoma. Based on length
of disease-free interval and advanced age, the patient was
started on our investigational treatment of cyclic-alternating
oestradiol and medroxyprogesterone acetate. Except for mild
mood changes and vaginal spotting, the patient tolerated the
treatment well. Her performance status improved and within
4 months, her disease was in partial remission. Sixteen
months later, however, she developed anorexia and fatigue.
She was taking oestradiol at the time. Symptoms resolved
with the institution of medroxyprogesterone acetate, but
recurred during each subsequent cycle of oestradiol. Symp-
toms became progressively more severe; and profound
nausea, vomiting, and diarrhea necessitated parenteral re-
hydration during the last two cycles. We considered disease
progression as a possible cause. We discontinued treatment
and expected to observe a hormone withdrawal antitumour
Table I Characteristics of responding patients according to presence
or absence of adrenal failure
Adrenal No adrenal P
Characteristics failure failure value*
Number 3 14
Age, median, years 69 62
(range) (60-71) (32-67)
mean, years 67 59 0.14
Treatment duration
median, months 25 16
(range) (25-39) (4-71 +)
mean, months 30 20
(± 1 s.d.) (±8) (± 19) 0.21
Weight gain
median, kg 5.9 1.2
(range) (4.5-9.1) (-13-8)
mean, kg 6.5 0.2
(± 1 s.d.) (2.4) (± 6.8) 0.025
Increase in hematocrit
median, % 6.9 1.1
(range) (3.9-9.1) (- 8.0-5.7)
mean, % 6.6 0.6
(± I s.d.) ( 2.6) ( 3.6) 0.046
*T test statistics.
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Table II Hormone levels of patients who developed adrenal insufficiency
Normal Time of determination
Value range At diagnosis At follow-up
ACTH, pgml-' 20-80
Case 1 23 25
Case 2
Case 3 - 25
Androstenedione, ngdl-' 50-200
Case 1 27 37
Case 2 <20 35
Case 3 - 200
Cortisol basal, mcgdl-' 7-25
Case 1 6.4* 0.7
Case 2 <0.5 5.9
Case 3 _ 30.0
Cortisol stimulated, mcg dl' > 50% above basal
Case 1 16.6* 9.8
Case 2 <0.5 24.4
Case 3 _ 39.0
Testosterone, ng dl- 28-85
Case 1 3 8
Case 2 <2 18
Case 3
Aldosterone, ngdl-' 9.4-33.8
Case 1 5.9 4.3
Case 2 7.0 5.0
Case 3
*9-alpha-fluorohydrocortisone was discontinued 48 h before test. Urinary
cortisol excretion was 10jxg 24 h-'.
effect, considering the excellent original response. Instead, the
patient became acutely sick, developed profound nausea,
vomiting, fatigue and anorexia. Within only a few days she
lost 5 kg of weight, became dehydrated, hypotensive, and
hyponatremic. After rehydration and treatment with 9-alpha-
fluorohydrocortisone was instituted, the tumour status was
assessed. We could not attribute her weakness, lethargy, and
anorexia to progression of the breast cancer, and no adrenal
metastases could be seen on a computed tomographic (CT)
scan. We withheld treatment with 9-alpha-fluorocortisone in
order to evaluate the adrenal function, but within 2 days the
patient became lethargic, polyuric, dehydrated, and lost 2 kg
of weight. Blood pressure dropped from 150/90 to
120/80 mm' Hg. Sodium was 122 meq 1-; potassium,
4.3meql-'; sodium excretion, 162meq 24h-'; and potas-
sium excretion, 14meq24h-'. Plasma levels of adrenal
steroids are listed in column I of Table II; the free urinary
cortisol excretion was 15 mcg 24 h-' (normal, 20-90 mcg
24 h-').
Based on these findings, we began substitution therapy
with daily 37.5mg of cortisone acetate and 0.2mg of 9-
alpha-fluorohydrocortisone. The patient's overall conditions
improved immediately and dramatically. Within a few days
she regained her weight, and blood pressure and sodium
metabolism normalised. Six weeks later, while plasma
aldosterone level remained still at 4.3 ngdl-', testosterone
and cortisol levels had increased to 12 ngdl-' and
31 mcgdl-', respectively. The doses of cortisone acetate and
of 9-alpha-fluorohydrocortisone were consequently reduced
to 25 mg and 0.1 mg, respectively, and after an additional 3
months they were reduced further to 12.5 mg and 0.05 mg,
respectively. The patient's conditions remained stable.
The patient's pituitary adrenal function was reevaluated 6
months after treatment with oestradiol/medroxyprogesterone
acetate had been discontinued. As shown in column 2 of
Table II, basal hormone levels were still low. The ACTH
level was 25 pgml', and the dehydroepiandrosterone level
was 14 ngdl'-l (normal, 140-1,010 ng dl-'). The tumour did
not respond to subsequent endocrine treatments, and the
patient died of widespread metastatic carcinoma 9 months
after her disease has become refractory to treatment with
oestradiol/medroxyprogesterone acetate. No autopsy was
performed.
Case 2: The second patient, a 62-year-old woman, de-
veloped recurrent breast carcinoma in regional soft tissues
and lymph nodes after a disease-free interval of 5 years. She
was given the same treatment of cyclic-alternating oestradiol
and medroxyprogesterone acetate. She tolerated the treat-
ment well and achieved a complete remission from her
disease for 25 months. At that time metastatic liver tumours
developed. Treatment was discontinued; where upon nausea,
vomiting, diarrhea, severe abdominal pain, and a 7 kg weight
loss, developed. The patient's plasma levels of adrenal
steroids are listed in column 1 of Table II.
No metastases to adrenal glands were seen on a CT scan
of the abdomen. The patient recovered after rehydration. No
substitution of adrenal hormones became necessary. Six
months later basal plasma cortisol level had recovered and
increased with stimulation, while the levels of other adrenal
steroids remained low (shown in column 2 of Table II). The
tumour resolved clinically completely on subsequent treat-
ment with chemotherapy, and the patient remained well 1+
years after the acute event.
Case 3: A 69-year-old woman presented with loco-
regionally advanced breast carcinoma with metastases to
bone and bone marrow. She was given the same cyclic-
alternating treatment with oestradiol and medroxy-
progesterone acetate. She tolerated the treatment well, and
her disease responded for 39 months, when bone tumours
began to reactivate.
In view of the long response, an hormone withdrawal
antitumour effect was expected, and no active treatment was
instituted. However, on her follow-up visit, 5 weeks later, the
patient reported anorexia, fatigue, nausea, vomiting and a
weight loss of 2+ kg. The only objective signs were weight
loss and a drop of the blood pressure from 150/100 to
120 80 mmHg. With the exception of a low stimulated corti-
sol level, there was no biochemical evidence of adrenal
insufficiency. Though the test results were not yet available,
we were alerted of the potential treatment toxicity and
initiated substitution therapy with corticosteroids. The
patients symptoms resolved promptly, and steroids could be
withdrawn 3 weeks later. The tumour responded to with-
drawal of oestradiol/medroxyprogesterone acetate and, the
patient continued to do well 2 years after this treatment was
discontinued.456 V. HUG et al.
Long-term treatment with cyclic-alternating oestradiol and
medroxyprogesterone acetate led to clinical adrenal
insufficiency in three of 30 treated or in three of 17 respond-
ing patients. Patients who developed adrenal failure received
treatment for longer, were older, and were more sensitive to
the anabolic effects of medroxyprogesterone acetate than
were patients who did not develop this particular treatment
toxicity. Steroid biosynthesis of all three adrenocortical layers
became suppressed. Two of the affected patients had ex-
tremely low plasma levels of adrenal corticosteroids, in par-
ticular of testosterone; but profound deficiency of
aldosterone gave rise to the leading clinical manifestations in
one patient. Two to 6 months were necessary for clinical
recovery, and more than 6 months were necessary for
biochemical recovery.
The progression of biochemical adrenal insufficiency to
clinically overt adrenal insufficiency was likely of multifact-
orial etiology and possibly related to the cyclical succession
of pharmacologically-dosed sex-steroid hormones, since
neither pharmacological doses of progestins (either megestrol
acetate or medroxyprogesterone acetate) nor cyclic-
alternating physiological doses of oestrogens and progestins
(used for contraception) are associated with this particular
treatment complication. The severity of pituitary-adrenal
suppression was possibly also related to treatment duration
(the improved antitumour effect obtained form oestrogen
priming leads to longer use of the treatment) and to pretreat-
ment condition of the adrenal gland (its functional capacity
declines with advancing age) (Montanini et al., 1988).
In summary, 18% of our patients receiving long term
treatment with cyclic-alternating hormones at pharma-
cological doses developed clinical signs and symptoms of
adrenal insufficiency. Since the pharmacological use of hor-
mones in combination is increasing, we feel it necessary to
alert physicians to this potentially life-threatening toxicity.
Thus, our observation suggest that combining hormones may
not only enhance their antitumour effect, but also their tox-
icity and the net gain in therapeutic index may not improve.
The authors would like to thank Ozella E. Walton for technical
assistance in the preparation of this manuscript and Walter Pagel for
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